Publications

Export 4352 results:
Sort by: Author [ Title  (Asc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V [W] X Y Z   [Show ALL]
:
Walid M.Mabrouk, ":" A numerical technique for an accurate determination of formation resistivity factor using FR-RO overlays method" ", Arabian Journal of Geosciences, vol. 8, issue 3, pp. 1291-1297, 2015.
<
Brooks, M. J., J. L. Sedillo, N. Wagner, W. Wang, A. S. Attia, H. Wong, C. A. Laurence, E. J. Hansen, and S. D. Gray-Owen, "Moraxella catarrhalis binding to host cellular receptors is mediated by sequence-specific determinants not conserved among all UspA1 protein variants", Infection and immunity, 2008/08/06, vol. 76, no. 11, pp. 5322-9, Nov, 2008. AbstractWebsite

The Moraxella catarrhalis ubiquitous surface proteins (UspAs) are autotransporter molecules reported to interact with a variety of different host proteins and to affect processes ranging from serum resistance to cellular adhesion. The role of UspA1 as an adhesin has been confirmed with a number of different human cell types and is mediated by binding to eukaryotic proteins including carcinoembryonic antigen-related cellular adhesion molecules (CEACAMs), fibronectin, and laminin. A distinct difference in the ability of prototypical M. catarrhalis strains to adhere to CEACAM-expressing cell lines prompted us to perform strain-specific structure-function analyses of UspA1 proteins. In this study, we characterized CEACAM binding by a diverse set of UspA1 proteins and showed that 3 out of 10 UspA1 proteins were incapable of binding CEACAM. This difference resulted from the absence of a distinct CEACAM binding motif in nonadhering strains. Our sequence analysis also revealed a single M. catarrhalis isolate that lacked the fibronectin-binding motif and was defective in adherence to Chang conjunctival epithelial cells. These results clearly demonstrate that UspA1-associated adhesive functions are not universally conserved. Instead, UspA1 proteins must be considered as variants with the potential to confer both different cell tropisms and host cell responses.

Attia, A. S., J. L. Sedillo, W. Wang, W. Liu, C. A. Brautigam, W. Winkler, and E. J. Hansen, "Moraxella catarrhalis expresses an unusual Hfq protein", Infection and immunity, 2008/03/26, vol. 76, no. 6, pp. 2520-30, Jun, 2008. AbstractWebsite

The Hfq protein is recognized as a global regulatory molecule that facilitates certain RNA-RNA interactions in bacteria. BLAST analysis identified a 630-nucleotide open reading frame in the genome of Moraxella catarrhalis ATCC 43617 that was highly conserved among M. catarrhalis strains and which encoded a predicted protein with significant homology to the Hfq protein of Escherichia coli. This protein, containing 210 amino acids, was more than twice as large as the Hfq proteins previously described for other bacteria. The C-terminal half of the M. catarrhalis Hfq protein was very hydrophilic and contained two different types of amino acid repeats. A mutation in the M. catarrhalis hfq gene affected both the growth rate of this organism and its sensitivity to at least two different types of stress in vitro. Provision of the wild-type M. catarrhalis hfq gene in trans eliminated these phenotypic differences in the hfq mutant. This M. catarrhalis hfq mutant exhibited altered expression of some cell envelope proteins relative to the wild-type parent strain and also had a growth advantage in a continuous flow biofilm system. The presence of the wild-type M. catarrhalis hfq gene in trans in an E. coli hfq mutant fully reversed the modest growth deficiency of this E. coli mutant and partially reversed the stress sensitivity of this E. coli mutant to methyl viologen. The use of an electrophoretic mobility shift assay showed that this M. catarrhalis Hfq protein could bind RNA derived from a gene whose expression was altered in the M. catarrhalis hfq mutant.

A
Kotb, M. H., O. W, T. El-Maghraby, M. El-Bedwihy, M. El-Tawdy, H. Moustafa, and A. Al-Nahhas, "A. The value of simultaneous Co-registration of 99mTc- MDP and 131Iodine in metastatic differentiated thyroid carcinoma", Nuclear Medicine Review , vol. 10, 2007.
Henderson, L., A. Wolfreys, J. Fedyk, C. Bourner, and S. Windebank, The ability of the Comet assay to discriminate between genotoxins and cytotoxins, : Oxford University Press and United Kingdom Environmental Mutagen Society, 1998. Abstract
n/a
Hallerstrom, M., C. B. von Stempel, A. Raheem, and M. Walkden, "Abnormal deep dorsal vein resulting in veno-occlusive erectile dysfunction.", BMJ case reports, vol. 2018, 2018. Abstract

A 59-year-old man with a 6-year history of erectile dysfunction presented to the andrology outpatient clinic. Multimodality assessment with ultrasound, MRI venography and fluoroscopic venography demonstrated an aberrant emissary vein arising from the corporal bodies causing venogenic erectile dysfunction. Selective coil embolisation of the collateral vein resulted in an almost immediate and sustained improvement in his erections.

Anantharaman, N., M. Ingremeau, M. Sabri, and B. Winn, "Absolutely Continuous Spectrum for Quantum Trees", Communications in Mathematical Physics, vol. 383, pp. 537-594, 2021. 200318ac.pdf
Abusteit, E. O., F. T. Corbin, D. P. Schmitt, J. W. Burton, D. A. Worsham, and L. Thompson Jr, "Absorption, translocation, and metabolism of metribuzin in diploid and tetraploid soybean (Glycine max) plants and cell cultures", Weed Science: JSTOR, pp. 618-628, 1985. Abstract
n/a
Saad, W. E., W. M. Darwish, M. G. Davies, and D. L. Waldman, "Abstract No. 65: Transhepatic dilation of anastomotic biliary strictures in liver transplant recipients: A comparison between a conventional balloon protocol vs. a combined cutting-conventional balloon protocol", Journal of Vascular and Interventional Radiology, vol. 21, issue 2: Elsevier, pp. S26-S27, 2010. Abstract
n/a
Saad, W., C. L. Anderson, W. M. Darwish, M. G. Davies, D. L. Waldman, J. F. Angle, U. C. Turba, S. S. Sabri, J. Stone, and T. Kitanosono, "Abstract No. 77: Comparison between the technical results of TIPS in liver transplant recipients and native (non-transplanted) patients", Journal of Vascular and Interventional Radiology, vol. 22, issue 3: Elsevier, pp. S35-S36, 2011. Abstract
n/a
Darwish, W. M., W. E. Saad, M. G. Davies, D. Butani, and D. L. Waldman, "Abstract No. 85: Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: Clinical outcome", Journal of Vascular and Interventional Radiology, vol. 21, issue 2: Elsevier, pp. S34, 2010. Abstract
n/a
Grant, D. A., E. Teng, R. O. Serpa, M. L. Prins, A. V. Ulyanova, P. F. Koch, M. R. Grovola, J. P. Harris, D. K. Cullen, and J. A. Wolf, "Abstracts from The 32nd Annual National Neurotrauma Symposium June 29–July 2, 2014 San Francisco, California", Journal of Neurotrauma, vol. 31, issue 12: Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA, pp. A-1-A-126, 2014. Abstract
n/a
Grant, D. A., E. Teng, R. O. Serpa, M. L. Prins, A. V. Ulyanova, P. F. Koch, M. R. Grovola, J. P. Harris, D. K. Cullen, and J. A. Wolf, Abstracts from The 32nd Annual National Neurotrauma Symposium June 29–July 2, 2014 San Francisco, California, , vol. 31, issue 12: Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA, pp. A - 1, 2014. Abstract
n/a
Ding, Y., M. S. Osman, and A. - M. Wazwaz, "Abundant complex wave solutions for the nonautonomous Fokas-Lenells equation in presence of perturbation terms", Optik, vol. 181, pp. 503-513, 2019.
Wenz, F., Y. Abo-Madyan, G. Welzel, and F. A. Giordano, "ABVD vs. radiotherapy in early stage Hodgkin’s lymphoma", Strahlentherapie und Onkologie, vol. 188, no. 8: Urban & Vogel, pp. 649, 2012. Abstract
n/a
Mikolajczak, A., N. A. Sallam, R. D. Singh, T. B. Scheidl, E. J. Walsh, S. Larion, C. Huang, and J. A. Thompson, "Accelerated developmental adipogenesis programs adipose tissue dysfunction and cardiometabolic risk in offspring born to dams with metabolic dysfunction", Am J Physiol Endocrinol Metab, vol. 321, issue 5, pp. E581-E591, 2021.
Mandouh, E. E., A. Gamal, A. Khaled, T. Ibrahim, A. G. Wassal, and E. Hemayed, "Accelerating Functional Verification Coverage Data Manipulation Using Map Reduce", in the Proceedings of The 2017 Design and Verification Conference (DVCon) Europe, Munich, Germany, October 16-17, 2017.
Sakr, F. Z., M. Taher, A. M. Ei-Bialy, and A. M. Wahba, "Accelerating Iris Recognition algorithms on GPUs", Biomedical Engineering Conference (CIBEC), 2012 Cairo International: IEEE, pp. 73–76, 2012. Abstract
n/a
Mandouh, E. E., and A. Wassal, "Accelerating the Debugging of FV Traces Using K-Means Clustering Techniques", in Proceedings of the 11th IEEE International Design & Test Symposium (IDT), Hammamet, Tunisia, December 18-20, 2016.
El Kassas, M., M. Alboraie, D. Omran, M. Salaheldin, M. N. Wifi, M. Elbadry, adel el tahan, S. Ezzat, E. Moaz, A. M. Farid, et al., "An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens", Expert Review of Gastroenterology & Hepatology, vol. 12, issue 12, pp. 1265-1272, 2018. single_centre_paper.pdf
El Kassas, M., M. Alboraie, D. Omran, M. Salaheldin, M. N. Wifi, M. Elbadry, adel el tahan, S. Ezzat, E. Moaz, A. M. Farid, et al., "An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.", Expert review of gastroenterology & hepatology, pp. 1-8, 2018 May 24. Abstract

BACKGROUND: A large Egyptian treatment program for HCV was launched in2014 after the introduction of direct-acting antiviral agents (DAAs). This program depended mainly on establishing specialized independent centres for HCV treatment. These centres represent the major strengths in the Egyptian model of care, as they provide integrated care for HCV patients and have enabled Egypt to treat more than one million patients in 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example of these specialized centres.

METHODS: The Egyptian experience in the management of HCV was evaluated by analysing the data of real-life HCV management in the NCVHTC from 2014 to 2017. Results of different treatment regimens in addition to their strengths, limitations and areas for improvement are discussed in this report.

RESULTS: A total of 7042 HCV patients have been evaluated for treatment in the NCVHTC. Among them, 5517 patients received treatment by seven different DAA regimens with excellent results.

CONCLUSIONS: All regimens were highly effective at treating HCV in a real-life setting, apart from SOF/RBV, which was the least effective. A nationwide screening program and enhancing the follow-up of treated patients are the main missing pillars in the Egyptian model.

El Kassas, M., M. Alboraie, D. Omran, M. Salaheldin, M. N. Wifi, M. Elbadry, adel el tahan, S. Ezzat, E. Moaz, A. M. Farid, et al., "An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.", Expert review of gastroenterology & hepatology, pp. 1-8, 2018 May 24. Abstract

BACKGROUND: A large Egyptian treatment program for HCV was launched in2014 after the introduction of direct-acting antiviral agents (DAAs). This program depended mainly on establishing specialized independent centres for HCV treatment. These centres represent the major strengths in the Egyptian model of care, as they provide integrated care for HCV patients and have enabled Egypt to treat more than one million patients in 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example of these specialized centres.

METHODS: The Egyptian experience in the management of HCV was evaluated by analysing the data of real-life HCV management in the NCVHTC from 2014 to 2017. Results of different treatment regimens in addition to their strengths, limitations and areas for improvement are discussed in this report.

RESULTS: A total of 7042 HCV patients have been evaluated for treatment in the NCVHTC. Among them, 5517 patients received treatment by seven different DAA regimens with excellent results.

CONCLUSIONS: All regimens were highly effective at treating HCV in a real-life setting, apart from SOF/RBV, which was the least effective. A nationwide screening program and enhancing the follow-up of treated patients are the main missing pillars in the Egyptian model.